How Malaria Works—and Why It Still Kills

A Parasite With a Double Life

Malaria is not caused by a virus or a bacterium. It is caused by a single-celled parasite of the genus Plasmodium, transmitted through the bite of an infected female Anopheles mosquito. Five species infect humans, but Plasmodium falciparum—dominant in sub-Saharan Africa—is responsible for the vast majority of deaths.

What makes malaria so resilient is the parasite's extraordinarily complex life cycle, which unfolds across two hosts: mosquitoes and humans. At each stage, the organism changes form, presenting different targets to the immune system and making a single vaccine or drug almost impossibly difficult to design.

Inside the Body: From Liver to Blood

When an infected mosquito bites, it injects microscopic sporozoites into the skin. These travel to the liver within minutes, invading liver cells where they multiply silently for 7 to 10 days—producing no symptoms at all. A single sporozoite can generate tens of thousands of daughter cells called merozoites.

When the liver cells burst, merozoites flood the bloodstream and invade red blood cells. Inside each cell, the parasite replicates again, producing roughly 16 new merozoites per cycle. When the red blood cell ruptures, the new parasites invade fresh cells—and the cycle repeats every 48 to 72 hours. This synchronized destruction of blood cells is what produces malaria's hallmark waves of high fever, chills, and sweating.

Some parasites take a different path, developing into sexual forms called gametocytes. When another mosquito feeds on the infected person, it picks up these gametocytes, and the cycle begins anew.

A Master of Disguise

Natural immunity to malaria is notoriously slow to develop and short-lived, even in people bitten hundreds of times. The reason lies in the parasite's sophisticated evasion tactics.

P. falciparum uses a strategy called antigenic variation: it constantly switches which surface proteins it displays on infected red blood cells. By the time the immune system mounts a response against one variant, the parasite has already changed its appearance. According to research published in Frontiers in Microbiology, this extensive diversity of surface antigens is one of the main obstacles to developing an effective vaccine.

The parasite also hides inside red blood cells, which lack the molecular machinery to alert the immune system to intruders. It can even suppress immune responses directly, reprogramming host cells to tolerate its presence. Research from Harvard T.H. Chan School of Public Health has shown that the parasite can shut down key genes, rendering itself "immunologically invisible."

Why Eradication Remains Elusive

Malaria is both preventable and treatable—yet it killed an estimated 610,000 people in 2024, according to the WHO World Malaria Report 2025. More than 434,000 of those deaths were children under five. A child still dies of malaria roughly every minute.

Several converging crises make the fight harder:

• Drug resistance: Resistance to artemisinin, the frontline treatment, has been confirmed or suspected in eight countries.
• Insecticide resistance: Pyrethroids—the main chemical used on bed nets—face resistance in 48 of 53 reporting countries.
• Diagnostic failures: Genetic deletions in the parasite can cause rapid diagnostic tests to return false negatives, now reported in 46 endemic countries.
• An invasive mosquito: Anopheles stephensi, an urban-dwelling, insecticide-resistant species, is expanding across Africa and threatens to bring malaria into cities.

Meanwhile, global funding reached just $3.9 billion in 2024—less than half the $9.3 billion the WHO says is needed.

New Vaccines Offer Hope

After decades of effort, two malaria vaccines are now WHO-recommended. RTS,S (Mosquirix), approved in 2021, and R21/Matrix-M, approved in 2023, both target the sporozoite stage. R21 showed 78% efficacy in clinical trials among young children—a breakthrough for a disease where even partial protection saves thousands of lives.

According to Medicines for Malaria Venture, 25 countries are now rolling out malaria vaccines, with demand projected to reach 80–100 million doses annually by 2030. Combined with bed nets, indoor spraying, and new drugs, vaccines represent a critical new layer of defense.

Since 2000, the global effort has averted an estimated 2.3 billion cases and saved 14 million lives. But with rising resistance, funding gaps, and a parasite that has evolved for millennia to outsmart its hosts, the road to eradication remains long—and the stakes could not be higher.